The development of the new cancer virus, cell therapy for ovarian cancer and the analysis of immune system response

我们已经开发了具有复制能力的减毒单纯疱疹病毒-1(HSV-1)突变体，并对其溶瘤活性进行了评估。然而，宿主免疫系统仍然是临床上有效地通过腹膜腔给药这些病毒的重要障碍。在这项研究中，我们研究了这些HSV-1突变体作为卵巢癌的溶瘤剂和人腹膜间皮细胞作为腹膜内治疗的载体细胞。我们的结果表明，这些HSV-1突变体对卵巢癌具有强大的溶瘤作用，利用载体细胞递送系统，基于病毒载量的放大，并可能避免中和抗体，可能会进一步增强这种作用。

We have developed replication-competent, attenuated herpes simplex virus-1(HSV-1) mutants, which have been evaluated for their oncolytic activities. However, the host immune system remains a significant obstacle to effective intraperitoneal administration of these viruses in the clinical setting. In this study, we investigated the use of these HSV-1 mutants as oncolytic agents against ovarian cancer and human peritoneal mesothelial cells as carrier cells for intraperitoneal therapy. Our results indicate that these HSV-1 mutants exerts a potent oncolytic effect on ovarian cancer, which may be further enhanced by the utilization of a carrier cell delivery system, based on amplification of viral load and possibly on avoidance of neutralizing antibodies.